GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.
GENFIT has successfully completed a non-dilutive royalty financing agreement with HCRx worth up to €185 million, receiving an immediate €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestones.
GENFIT's partner Ipsen is making strides with Iqirvo® (elafibranor) for PBC, with encouraging U.S. launch feedback and European reimbursement approvals.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.